Results 21 to 30 of about 47,341 (232)

Antidepressants versus placebo for depression in primary care [PDF]

, 2009
Background Concern has been expressed about the relevance of secondary care studies to primary care patients specifically about the effectiveness of antidepressant medication.
Arroll, Bruce, Blashki, Grant, Elley, C. Raina, Fishman, Tana, Goodyear-Smith, Felicity A., Kenealy, Tim, Kerse, Ngaire, MacGillivray, Stephen   +7 more
core   +3 more sources

Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. [PDF]

, 2012
Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability due to an expansion in the full mutation range (>200 CGG repeats) of the promoter region of the FMR1 gene leading to gene silencing.
Borodyanskara, Mariya, Hagerman, Randi J, Schneider, Andrea, Winarni, Tri Indah   +3 more
core   +3 more sources

Quantitative cross-species extrapolation between humans and fish: The case of the anti-depressant fluoxetine [PDF]

, 2014
This article has been made available through the Brunel Open Access Publishing Fund.Fish are an important model for the pharmacological and toxicological characterization of human pharmaceuticals in drug discovery, drug safety assessment and ...
ABA Boxall, AC Altamura, AC Johnson, Anna de Polo, BJ Ring, C Charlier, C Hiemke, C Lillesaar, C Maximino, CA LaLone, CB Eap, D Baldwin, D Kokel, DB Huggett, DJ Caldwell, DS Baldwin, ED Levin, EJ Perkins, FM McRobb, G Jannuzzi, GG Gould, Grace H. Panter, GT Ankley, J Cachat, J Klooster, J Kristensen, J Lundmark, J Rihel, J Rihel, JA Mennigen, JD Amsterdam, JG Kohlert, Jodi Pawluski, John P. Sumpter, JP Berninger, JP Seiler, JP Sumpter, JP Sumpter, JT Pittman, JV Goldstone, K Kuemmerer, KD Oakes, L Bjerkenstedt, L Fjordside, L Gunnarsson, L Ibrahim, L Margiotta-Casaluci, LD Ellis, Luigi Margiotta-Casaluci, M Rand-Weaver, M Schulz, M Sundvik, M Wolman, MA Lopez-Patino, Mariann Rand-Weaver, Matthew J. Winter, MC Celander, MG Scordo, MJ Airhart, MJ Owens, MJ Winter, MS Lipsky, MW Kelly, PD Anderson, RF Bergstrom, RJ Egan, Rob I. Cumming, RY Wong, SC Baraban, SC Dulawa, SH Preskorn, SH Preskorn, Stewart F. Owen, TJ Runnalls, TR Norman, TW Valenti Jr, TW Valenti Jr, WJAJ Smeets, YH Zhang, YJ Kim, Z Bencan   +80 more
core   +7 more sources

Treatment for depression following mild traumatic brain injury in adults: A meta-analysis [PDF]

, 2013
Primary objective: Development of depression after TBI is linked to poorer outcomes. The aim of this manuscript is to review evidence for the effectiveness of current treatments.
Barker-Collo, Suzanne, Starkey, Nicola J., Theadom, Alice   +2 more
core   +2 more sources

Pharmacotherapy or Psychotherapy? Selective Treatment Depression in The Infertile Women with Recurrent Pregnancy Loss: A Triple-Arm Randomized Controlled Trial [PDF]

International Journal of Fertility and Sterility, 2022
Background: Recurrent pregnancy loss (RPL) and infertility are associated with significant psychiatric complications.The study aimed to investigate the effectiveness of cognitive behavioral therapy (CBT) and sertralinein the treatment of in depression ...
Zahra Basirat, Farzan Kheirkhah, Mahbobeh Faramarzi, Sedigheh Esmaeilzadeh, sorraya khafri, Zahra Tajali   +5 more
doaj   +1 more source

Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression [PDF]

, 2012
Background: Randomized, double-blind, placebo-controlled trials constitute the gold standard in clinical research when testing the efficacy of new psychopharmacological interventions in the treatment of major depression.
A Cipriani, A Cipriani, A Hrobjartsson, A Loh, Andrea Pfennig, BR Rutherford, CP Gross, DE Moerman, DL Sackett, EA Largent, Emanuel Severus, F Seemuller, FG Miller, Florian Seemüller, G Parker, GI Papakostas, H Brody, H Brody, Hans-Jürgen Möller, HJ Moller, HJ Moller, HJ Moller, HU Wittchen, HV Krell, J Odgaard-Jensen, L Colloca, L Colloca, M Sinyor, MA Posternak, ME Wechsler, Michael Bauer, Michael Berger, Michael Obermeier, Michael Riedel, R Jones, RE Drake, RW Lam, Sandra Dittmann, SB Patten, SH Kennedy, Sophia Frangou, SR Wisniewski, U Hegerl, U Hegerl   +43 more
core   +3 more sources

Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults

Frontiers in Pediatrics, 2019
Objective: Due to potential disease and drug interactions, the appropriate sertraline starting dose and titration range may require adjustment in pediatric patients living with HIV.
Nathan John Hanan, Mary Elizabeth Paul, Yanling Huo, Suad Kapetanovic, Elizabeth Smith, George Siberry, Pim Brouwers, Bobbie Graham, Benjamin Johnston, Edmund V. Capparelli, Edmund V. Capparelli, Brookie M. Best, Brookie M. Best   +12 more
doaj   +1 more source

Sertraline for Functional Recovery After Acute Ischemic Stroke: A Prospective Observational Study

Frontiers in Neurology, 2021
Background: Neuroprotective and neurorestorative effects have been postulated for selective serotonin-reuptake inhibitors (SSRI). We hypothesized that sertraline, which is characterized by less severe adverse effects and more stable pharmacokinetics than
Isabella Stuckart, Timo Siepmann, Christian Hartmann, Lars-Peder Pallesen, Annahita Sedghi, Jessica Barlinn, Heinz Reichmann, Volker Puetz, Kristian Barlinn   +8 more
doaj   +1 more source

Sertraline

Reactions Weekly, 2006
europepmc   +2 more sources

Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease

Neurobiology of Disease, 2008
Huntington's disease (HD) is an inherited progressive neurodegenerative disorder resulting from CAG repeat expansion in the gene that encodes for the protein huntingtin.
Wenzhen Duan, Qi Peng, Naoki Masuda, Eric Ford, Erik Tryggestad, Bruce Ladenheim, Ming Zhao, Jean Lud Cadet, John Wong, Christopher A. Ross   +9 more
doaj   +1 more source